Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

BTG acquires diabetes and neurodegeneration programs from King's College

May 7, 2004

Approval of rhBMP for orthopedic trauma patients

May 7, 2004

Effective normalization of IGF-1 levels achieved with pegvisomant in acromegaly

May 7, 2004

Therapeutic benefits of pioglitazone in several diabetic complications

May 7, 2004

Synergistic effects of AM-251 and an opioid antagonist on food intake in mice

May 7, 2004

Exenatide improves glycemic control in diabetics receiving metformin and/or sulfonylureas

May 6, 2004

Teriparatide reported to reduce back pain in postmenopausal osteoporosis

May 6, 2004

European pivotal phase III trial for rhC1INH commences

May 6, 2004

New orexin antagonists for obesity and sleep disorders claimed by GSK

May 5, 2004

Novel estrogen receptor modulators under study at Merck

May 5, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.